Equipotent doses of daunorubicin and idarubicin for AML

a meta-analysis of clinical trials versus in vitro estimation

Sunil Adige, Rena G. Lapidus, Brandon A. Carter-Cooper, Alison Duffy, Ciera Patzke, Jennie Y. Law, Maria R. Baer, Nicholas P. Ambulos, Ying Zou, Søren M. Bentzen, Ashkan Emadi

Research output: Contribution to journalArticle

Abstract

In the treatment of acute myeloid leukemia (AML), the “7 + 3”-based strategy, combining cytarabine 100–200 mg/m2 for 7 days with an anthracycline for 3 days, remains the standard of care for younger and medically fit patients. Daunorubicin (DNR) and idarubicin (IDA) are the two anthracyclines most commonly used. DNR and IDA are used interchangeably with different conversion factors, as there is no high-level evidence on the equipotency of these two agents for AML treatment. To determine the equipotent doses of DNR and IDA, we first systematically reviewed studies directly comparing the clinical outcomes of AML induction therapy utilizing DNR and IDA. We found 15 articles that met our inclusion criteria and compared time-to-event survival end points as well as complete remission rates post-induction. The DNR:IDA equipotency ratio was estimated at 5.90 with 95% confidence interval (CI) 1.7–20.7. To validate the estimate from our meta-analysis biologically, we conducted in vitro tests comparing anti-AML activity of DNR and IDA against six AML cell lines and two primary AML cells from patients with different cytogenetic and molecular characteristics. Based on these in vitro data, the equipotency dose ratio between DNR and IDA was 4.06 with 95% CI 3.64–4.49. Combining the estimates from the meta-analysis and the in vitro data using inverse-variance weighting, the current best estimate of the DNR:IDA equipotent ratio is 4.1 with 95% CI 3.9–4.3. This estimate, however, is largely driven by the in vitro chemo-sensitivity data. Given clinical studies demonstrating the safety of IDA at higher doses, our work implies that dose intensification of IDA could be investigated in future clinical trials in AML.

Original languageEnglish (US)
Pages (from-to)1105-1112
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume83
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Idarubicin
Daunorubicin
Acute Myeloid Leukemia
Meta-Analysis
Clinical Trials
Anthracyclines
Myeloid Cells
Confidence Intervals
In Vitro Techniques
Cytarabine
Standard of Care
Cytogenetics
Therapeutics
Cells

Keywords

  • Acute myeloid leukemia (AML)
  • Anthracycline
  • Chemotherapy equipotency
  • Daunorubicin
  • Idarubicin
  • Meta-analysis

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Equipotent doses of daunorubicin and idarubicin for AML : a meta-analysis of clinical trials versus in vitro estimation. / Adige, Sunil; Lapidus, Rena G.; Carter-Cooper, Brandon A.; Duffy, Alison; Patzke, Ciera; Law, Jennie Y.; Baer, Maria R.; Ambulos, Nicholas P.; Zou, Ying; Bentzen, Søren M.; Emadi, Ashkan.

In: Cancer Chemotherapy and Pharmacology, Vol. 83, No. 6, 01.06.2019, p. 1105-1112.

Research output: Contribution to journalArticle

Adige, S, Lapidus, RG, Carter-Cooper, BA, Duffy, A, Patzke, C, Law, JY, Baer, MR, Ambulos, NP, Zou, Y, Bentzen, SM & Emadi, A 2019, 'Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation', Cancer Chemotherapy and Pharmacology, vol. 83, no. 6, pp. 1105-1112. https://doi.org/10.1007/s00280-019-03825-2
Adige, Sunil ; Lapidus, Rena G. ; Carter-Cooper, Brandon A. ; Duffy, Alison ; Patzke, Ciera ; Law, Jennie Y. ; Baer, Maria R. ; Ambulos, Nicholas P. ; Zou, Ying ; Bentzen, Søren M. ; Emadi, Ashkan. / Equipotent doses of daunorubicin and idarubicin for AML : a meta-analysis of clinical trials versus in vitro estimation. In: Cancer Chemotherapy and Pharmacology. 2019 ; Vol. 83, No. 6. pp. 1105-1112.
@article{a7b627cbd229459d9a6a7626ef678a60,
title = "Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation",
abstract = "In the treatment of acute myeloid leukemia (AML), the “7 + 3”-based strategy, combining cytarabine 100–200 mg/m2 for 7 days with an anthracycline for 3 days, remains the standard of care for younger and medically fit patients. Daunorubicin (DNR) and idarubicin (IDA) are the two anthracyclines most commonly used. DNR and IDA are used interchangeably with different conversion factors, as there is no high-level evidence on the equipotency of these two agents for AML treatment. To determine the equipotent doses of DNR and IDA, we first systematically reviewed studies directly comparing the clinical outcomes of AML induction therapy utilizing DNR and IDA. We found 15 articles that met our inclusion criteria and compared time-to-event survival end points as well as complete remission rates post-induction. The DNR:IDA equipotency ratio was estimated at 5.90 with 95{\%} confidence interval (CI) 1.7–20.7. To validate the estimate from our meta-analysis biologically, we conducted in vitro tests comparing anti-AML activity of DNR and IDA against six AML cell lines and two primary AML cells from patients with different cytogenetic and molecular characteristics. Based on these in vitro data, the equipotency dose ratio between DNR and IDA was 4.06 with 95{\%} CI 3.64–4.49. Combining the estimates from the meta-analysis and the in vitro data using inverse-variance weighting, the current best estimate of the DNR:IDA equipotent ratio is 4.1 with 95{\%} CI 3.9–4.3. This estimate, however, is largely driven by the in vitro chemo-sensitivity data. Given clinical studies demonstrating the safety of IDA at higher doses, our work implies that dose intensification of IDA could be investigated in future clinical trials in AML.",
keywords = "Acute myeloid leukemia (AML), Anthracycline, Chemotherapy equipotency, Daunorubicin, Idarubicin, Meta-analysis",
author = "Sunil Adige and Lapidus, {Rena G.} and Carter-Cooper, {Brandon A.} and Alison Duffy and Ciera Patzke and Law, {Jennie Y.} and Baer, {Maria R.} and Ambulos, {Nicholas P.} and Ying Zou and Bentzen, {S{\o}ren M.} and Ashkan Emadi",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s00280-019-03825-2",
language = "English (US)",
volume = "83",
pages = "1105--1112",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Equipotent doses of daunorubicin and idarubicin for AML

T2 - a meta-analysis of clinical trials versus in vitro estimation

AU - Adige, Sunil

AU - Lapidus, Rena G.

AU - Carter-Cooper, Brandon A.

AU - Duffy, Alison

AU - Patzke, Ciera

AU - Law, Jennie Y.

AU - Baer, Maria R.

AU - Ambulos, Nicholas P.

AU - Zou, Ying

AU - Bentzen, Søren M.

AU - Emadi, Ashkan

PY - 2019/6/1

Y1 - 2019/6/1

N2 - In the treatment of acute myeloid leukemia (AML), the “7 + 3”-based strategy, combining cytarabine 100–200 mg/m2 for 7 days with an anthracycline for 3 days, remains the standard of care for younger and medically fit patients. Daunorubicin (DNR) and idarubicin (IDA) are the two anthracyclines most commonly used. DNR and IDA are used interchangeably with different conversion factors, as there is no high-level evidence on the equipotency of these two agents for AML treatment. To determine the equipotent doses of DNR and IDA, we first systematically reviewed studies directly comparing the clinical outcomes of AML induction therapy utilizing DNR and IDA. We found 15 articles that met our inclusion criteria and compared time-to-event survival end points as well as complete remission rates post-induction. The DNR:IDA equipotency ratio was estimated at 5.90 with 95% confidence interval (CI) 1.7–20.7. To validate the estimate from our meta-analysis biologically, we conducted in vitro tests comparing anti-AML activity of DNR and IDA against six AML cell lines and two primary AML cells from patients with different cytogenetic and molecular characteristics. Based on these in vitro data, the equipotency dose ratio between DNR and IDA was 4.06 with 95% CI 3.64–4.49. Combining the estimates from the meta-analysis and the in vitro data using inverse-variance weighting, the current best estimate of the DNR:IDA equipotent ratio is 4.1 with 95% CI 3.9–4.3. This estimate, however, is largely driven by the in vitro chemo-sensitivity data. Given clinical studies demonstrating the safety of IDA at higher doses, our work implies that dose intensification of IDA could be investigated in future clinical trials in AML.

AB - In the treatment of acute myeloid leukemia (AML), the “7 + 3”-based strategy, combining cytarabine 100–200 mg/m2 for 7 days with an anthracycline for 3 days, remains the standard of care for younger and medically fit patients. Daunorubicin (DNR) and idarubicin (IDA) are the two anthracyclines most commonly used. DNR and IDA are used interchangeably with different conversion factors, as there is no high-level evidence on the equipotency of these two agents for AML treatment. To determine the equipotent doses of DNR and IDA, we first systematically reviewed studies directly comparing the clinical outcomes of AML induction therapy utilizing DNR and IDA. We found 15 articles that met our inclusion criteria and compared time-to-event survival end points as well as complete remission rates post-induction. The DNR:IDA equipotency ratio was estimated at 5.90 with 95% confidence interval (CI) 1.7–20.7. To validate the estimate from our meta-analysis biologically, we conducted in vitro tests comparing anti-AML activity of DNR and IDA against six AML cell lines and two primary AML cells from patients with different cytogenetic and molecular characteristics. Based on these in vitro data, the equipotency dose ratio between DNR and IDA was 4.06 with 95% CI 3.64–4.49. Combining the estimates from the meta-analysis and the in vitro data using inverse-variance weighting, the current best estimate of the DNR:IDA equipotent ratio is 4.1 with 95% CI 3.9–4.3. This estimate, however, is largely driven by the in vitro chemo-sensitivity data. Given clinical studies demonstrating the safety of IDA at higher doses, our work implies that dose intensification of IDA could be investigated in future clinical trials in AML.

KW - Acute myeloid leukemia (AML)

KW - Anthracycline

KW - Chemotherapy equipotency

KW - Daunorubicin

KW - Idarubicin

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=85065188866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065188866&partnerID=8YFLogxK

U2 - 10.1007/s00280-019-03825-2

DO - 10.1007/s00280-019-03825-2

M3 - Article

VL - 83

SP - 1105

EP - 1112

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -